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1. Introduction
“Cardiac output the “Holy Grail” of haemodynamic monitoring”
Physicians have been assessing the circulation long before the birth of Christ (BC). The
Egyptian physicians used simple palpation of the pulse and the use of the pulse in Chinese
medicine dates back over two thousand years. However, it was not until the 1940s that the
clinical sphygmomanometer was invented, and blood pressure measurement became rou‐
tinely available [1].Today pulse rate and blood pressure measurement is performed in almost
every patient.
Cardiac output is the volume of blood that is pumped by the heart around the systemic
circulation in a given time period, usually one minute. It is equal to the volume pumped out
by the heart in one contraction, known as stroke volume, multiplied by heart rate. The need
to measure cardiac output in a clinical setting arose in the 1970s because of the development
of intensive care units and the increasing need to manage unstable patients during high risk
surgery. In parallel with these clinical developments the technology also became available to
make more sophisticated cardiac output monitors and in particular monitors that can be used
continuously at the bedside.
When evaluating the circulation, and thus haemodynamics, a very simply model can be drawn
of the heart pumping blood through the arteries to peripheral capillaries and then returning to
the heart via the veins. The haemodynamics of the model has flow, the cardiac output, leaving
the heart, and passing through a resistance, the peripheral capillaries. Blood pressure is gener‐
ated in the arteries by the heart pumping against this resistance. A very simple formula exists
that describes the model of Blood Pressure = Cardiac Output x Peripheral Resistance, which is
often compared to Ohm’s law for electricity (i.e. Voltage = Current x Resistance).
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Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
During clinical assessment pulse rate and blood pressure are very easy to measure. However,
cardiac output and peripheral resistance are much less easy to obtain. Usually, the physician is
only able to measure the pulse rate, and thus does not know how much blood the heart pumps
each minute, nor the degree of the peripheral vasoconstriction. Knowing these variables be‐
comes important when treating critically ill patients with low blood pressures who may be ei‐
ther hypovolaemic or septic, as it helps one to differentiate between the two conditions.
Cardiac output has proved very difficult to measure reliably in the clinical setting. The Fick
method is considered the most accurate method and gold standard. It involves measuring
oxygen uptake by the body and comparing oxygen content in arterial and venous blood
samples. It is based on a very simple principle that blood flow through an organ is related to
the uptake of a marker (oxygen) and the difference in concentration of that marker between
blood entering (arterial) and blood leaving (venous) that organ, in the case of the Fick meth‐
od, the heart and lungs. However, the method is cumbersome and time consuming, and
usually performed in the laboratory. It is not suitable for bedside clinical use. The concept of
using a marker is also used in other methods of cardiac output measurement, such as a dye
and thermo (i.e. cold solution) dilution. Alternatively, a flow probe can be placed around the
aorta, but this is highly invasive requiring surgery to access the heart or a beam aimed at the
aorta that detects some property of flowing blood, such as the Doppler shift when using ul‐
trasound. A secondary effect of blood flow or the action of the heart can also be used as a
surrogate, such as bioelectrical changes in the thorax or the arterial blood pressure wave.
What makes cardiac output so difficult to measure accurately in the clinical setting, when
compared to other haemodynamic variables, is its dispersion as blood travels away from the
heart. Whereas the pulse rate and blood pressure can be measured from any location in the
arterial tree, such as the arm, cardiac output should ideally be measured at its origin the as‐
cending aorta, before it is split up into smaller regional blood flows.
Because of the clinical desire to known some patients’ cardiac output and the inherent diffi‐
culties encountered when measuring cardiac output, developing a reliable bedside cardiac
output monitoring has become the “Holy Grail” of haemodynamic monitoring.
In this chapter, I will review the main clinical methods available for measuring cardiac out‐
put and address the important issue of how they are evaluated.
2. Historical perspective
2.1. Earliest theories and methods
In the second century AD the Greek physician Galen taught his students that there were two
distinct types of blood, nutritive venous blood arising from the liver and vital arterial blood
arising from the heart. Galen believed that the heart acted not as pump, but sucked in blood
from the veins which passed through tiny pores in the septum. Galen’s explanation was be‐
lieved until the beginning of the seventeenth century when an English physician William
Harvey described the true nature of the circulation with the heart pumping blood around a
system of arteries, capillaries and veins.
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It was not until 1870 that cardiac output was first measured by the German physician and
physiologist Adolf Fick using an oxygen uptake method. The Fick method was later modified
in 1897 by Stewart to use a continuous saline infusion and then in 1928 by Hamilton to use a
bolus injection of dye technique [2,3]
2.2. Dye dilution methods
The Stewart-Hamilton dye dilution method to measure cardiac output was one of the earliest
to be used clinically. In the 1950’s indocyanine green dye became available clinically and was
used to measure cardiac output, as well as blood volume and liver blood flow. However,
sampling of arterial blood for dye levels was messy. A photocell detector placed on a finger
was developed. Today, lithium dilution is the main indicator dilution technique in clinical use
[4] and it is also a popular method in veterinarian practice.
2.3. The Swan-Ganz catheter
The idea of using a cold temperature solution as an indicator, or thermodilution, dates back
to the 1950’s. At first fine catheter tubes were placed in the pulmonary artery, but this proved
very difficult to perform clinically. The idea of using an inflated balloon to float the catheter
tip into position was credited to Swan in 1970 and the triple lumen pulmonary artery catheter
(PAC) with a thermistor at its tip to Ganz in 1971 [5,6]. Their PAC was produced by the
Edwards Laboratory Company. The PAC became the principle method of measuring cardiac
output and reached its peak usage by the end of the 1980’s with sales worldwide of 1 to 2
million catheters per year. However, doubts about its clinical usefulness arose in the 1980’s [7],
which were later confirmed by several multicentre clinical trials [8,9]. Since the 1990’s there
has been a major decline in the use of the PAC catheter [10] as alternative technologies such a
TOE have become available. Today, many anaesthetists and critical care doctors are unfamiliar
with using PACs. Only a few companies worldwide still manufacture PACs notably Arrow
International (Reading, PA, USA) and Edwards Lifesciences (Irvine, CA, USA). More sophis‐
ticated multifunction PACs are now being sold that measure continuous cardiac output using
a heated wire and mixed venous oxygen saturation.
Minimally invasive cardiac out monitoring (MICOM) that measured cardiac output continu‐
ously at the bedside started to become available in the 1970’s with the emergence of micro‐
processor and computer technology. Today they have become the main focus of clinical
monitoring of cardiac output.
3. Background to main methods
3.1. Bioimpedance
In 1957 Nyboer made the observation that the cardiac cycle was associated with repetitive
changes in thoracic impedance and that stroke volume could be estimated from the area under
the curve of the resulting impedance waveform. In 1966 Kubicek applied this observation to
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developing a method that could measure cardiac output in space by astronauts. Later he
developed the first commercial impedance cardiograph, the Minnesota [11]. In the 1980’s the
BoMed NCCOM3 (BoMed Ltd., Irvine, CA, USA) (Figure 1) was developed by Bernstein and
Sramek [12]. It used a modified Kubicek method to calculate cardiac output. It also automated
the process calculating cardiac output, and provided continuous cardiac output readings in
real-time. Thus, the first continuous MICOM had been developed.
Figure 1. The BoMed NCCOM3. It connects to the patients using eight skin surface electrodes applied to the mid-neck
and lower chest at the level of the diaphragm. Two additional ECG electrodes can be added. The BoMed is calibrated
by inputting the patient’s height and weight. Cardiac output and related bioimpedance variables are displayed as
numbers. Data is averaged over 16 heart-beats.
Unfortunately, the BoMed had problems with its reliability and was never was accepted
into  clinical  practice  [13].  The  presence  of  lung  fluid  corrupted  impedance  readings
[14,15]  and it  was never determined with any certainty what the BoMed actually meas‐
ured [16].  A digitalized version is  still  marketed and called the  BioZ (CardioDynamics,
San Diego,  CA,  USA).  A number  of  companies  have  tried over  the  years  to  produce  a
more reliable version, but none have been very successful [17]. There is a haemodynamic
monitoring system that  incorporates  bioimpedance  cardiac  output  as  one  of  its  modali‐
ties  call  the Task-Force Monitor  (CNSystems,  Graz,  Austria).  It  is  used mainly to  study
autonomic responses such as syncopy and head up tilting. There is also a device on the
market  called the NICOM (Cheetah Medical  Ltd.,  Tel-Aviv,  Israel)  that  uses  a  principle
call  bioreactance,  which measures shifts  in alternating current phase,  rather than electri‐
cal  resistance.  Potentially,  this device may be immune to the problems that afflicted the
BoMed, but good validation data are still needed.
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3.2. Doppler ultrasound
Ultrasound was first described in 1842. It was introduced into clinical practice in the 1950s by
Ian Donald, a Scotsman. Echocardiography was developed in 1960’s and used pulsed ultra‐
sound for imaging. The measurement of blood flow using Doppler ultrasound was developed
later to detect aortic and peripheral blood flow using continuous wave Doppler systems. In the
1980’s Singer a London critical care physician was instrumental in the clinical development of
oesophageal Doppler cardiac output monitoring [18]. In the early 1990’s several prototype
monitor and probe systems were developed such as the Hemosonic 1000, (Arrow Internation‐
al, Reading, PA, USA), and the Abbott ODM II, (Abbott Laboratories, Chicago, Il, USA). The
only successful model has been the CardioQ, (Deltex Medical, Chichester, England) released in
the early1990’s. In early 2000 an external continuous wave Doppler system was developed
called the USCOM, (USCOM Ltd., Sydney, Australia). Previously one had to use echocardiog‐
raphy machines with limited Doppler capabilities for external monitoring. The USCOM meas‐
ures cardiac output from both the ascending aorta and pulmonary artery using a hand held
probe placed over the anterior neck (i.e. thoracic inlet) or left anterior chest wall (i.e. 3th to 5th in‐
tercostals spaces). Thus, the USCOM measures cardiac output intermittently.
3.3. Pulse contour analysis
Noninvasive continuous blood pressure measurement using a pneumatic finger cuff (i.e.
plethysmography) was developed over 30-year ago. In 1993 Wesseling et al described a method
of using the finger cuff arterial pressure wave to derive cardiac output [19]. Their method
known as “Model Flow” was incorporated into the Finapres series of noninvasive continuous
blood pressure monitors. Currently, the manufacturers produce the Nexfin, (BMEYE, Am‐
sterdam, Netherlands).
Systems that used the arterial blood pressure trace to measure cardiac output were later devel‐
oped. In 1997 the first commercial system, the PiCCO (Pulsion, Munich, Germany) was re‐
leased.  The PiCCO was calibrated using transpulmonary thermodilution and monitored
cardiac output from a femoral arterial line. Since, several other systems have been developed
including in 2002 the LiDCO-plus (and later rapid), (LiDCO Ltd., Cambridge, England), and in
2004 the FloTrac-Vigileo, (Edwards Lifesciences, Irvine, CA, USA). Early versions of these
monitors relied on external calibration, usually by thermodilution. However, more recent ver‐
sions self-calibrate using patient demographic data. Pulse contour monitoring of cardiac out‐
put  has  not  proved  all  that  successful  and  current  systems  are  unreliable  when  large
fluctuations in peripheral resistance occur [20]. Recently there has been a change in the market‐
ing policy. The focus is now towards “functional haemodynamic variables”, such as pulse
pressure and stroke volume variation in response to fluid and postural challenges.
3.4. Other methods
Several other novel techniques of measuring cardiac output have also been developed. In the
1970’s researchers explored the possibility of using the mechanical impulse produced by heart
as it contracted. In the 1990’s a modified Fick method based on carbon dioxide rebreathing
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that used a special breathing circuit extension loop was developed call the NICO (Respironics,
Philips Healthcare, USA). The NICO is still produced but its use is restricted to intubated and
ventilated patients (Figure 2).
Figure 2. Elaborate NICO rebreathing loop and circuit attachment that was added to the patient’s breathing circuit
when performing the partial carbon dioxide rebreathing method.
In 2004 a device that used the time lags between the ECG and pulse oximetry signals was
developed called the FloWave 1000, (Woolsthorpe Technologies, Brentwood, TN, USA). A
Japanese group has recently developed a similar device called the esCCO monitor (Nihon
Kohden, Tokyo, Japan) [21]. The esCCO also calculates pulse wave transit time from the ECG
and pulse oximetry signal which it uses to calibrate the arterial pressure derived cardiac output
(Figure 3).
Figure 3. Illustration of the pulse wave transit time method used by the esCCO monitor. (Image from Nihon Kohden)
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4. Description of the main methods
4.1. Bioreactance
To understand how the bioreactance method (NICOM, Cheetah Medical) works one first must
understanding bioimpedance cardiac output. The older bioimpedance method involved detec‐
tion of electrical resistance changes within the thorax. A high-frequency (50-100 kHz) low am‐
plitude alternating current (<4mA), is passes between skin electrodes placed around the neck
and upper abdomen. Inner current sensing skin electrodes detect voltage changes across the
thorax and thus the impedance signal produced by the cardiac cycle (Figure 4). Originally,
band electrodes were uses, but in the BoMed this was changed to eight dot electrodes. Bioimpe‐
dance is safe electrically because of the high frequency and low amperage of the current. The
only report of injury with its use has been a pacemaker malfunction [22].
Figure 4. Electrode configurations used by different bioimpedance devices. The BoMed used an eight electrode con‐
figuration with outer current injecting and inner current sensing skin dot electrodes. Some other devices were de‐
signed with fewer but larger patch electrodes on the head and lower torso (current injecting) and neck and lower
thorax (current sensing). The bioreactance system (NICOM) also uses a four dual dot electrode configuration with the
neck electrodes placed slightly lower at the level of the clavicles.
Minimally Invasive Cardiac Output Monitoring in the Year 2012
http://dx.doi.org/10.5772/54413
51
In the original description of the impedance method the area under the bioimpedance signal
curve during systole was used to estimate cardiac output. To simply the method Kubicek et al
used the differential signal and its peak reading (dZ/dt(max)) as a surrogate for aortic blood
flow [11]. The method also involves measuring the left ventricular ejection time (LVET) from
the impedance signal (Figure 5). dZ/dt (max) multiplied by LVET provides stroke volume, but
the reading still needs to be calibrated. Cardiac output is calculated by multiplying by heart
rate. Other bioimpedance variables measured from the waveforms include: (i) the thoracic im‐
pedance which can be used as an index of lung fluid, (ii) the systolic time intervals, pre ejection
period (PEP) and LVET, which can be used to calculate ejection fraction and (iii) the second dif‐
ferential (i.e. d2Z/dt2(max)) which can be used as an index of contractility.
Figure 5. The bioimpedance method uses both the impedance signal (Z – upper waveform) and the differential signal
(dZ/dt – lower waveform). From the differential signal the flow variable dZ/dt(max) is measured. The time variable
LVET is also measured. A number of other indices that reflect lung fluid and contractility are also measured.
Bioreactance uses a different electrical signal. It detects a property of alternating current called
phase. An alternating current has a sinusoidal waveform. As the current flows through
different body tissues its passage is delayed by capacitive and inductive tissue effects (X) which
cause a shift in its phase. As blood volume in the central thorax region varies with the cardiac
cycle so does the phase shift of the current. Like resistance when measuring bioimpedance, a
signal of the phase shift (bioreactance signal) can be plotted and from it variables that reflected
blood flow (dX/dt(max)) and ventricular ejection time are measured (Figure 6). It is thought
that the bioreactance signal is less affected by the factors that troubled the bioimpedance
method, such as lung water [15].
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Figure 6. The steps in deriving bioreactance cardiac output (Images from Cheetah Medical).
Like all surrogate cardiac output methods the bioreactance method needs to be calibrated.
When using bioimpedance this requires estimation of the volume of electrically participating
tissue (VEPT) lying between the current sensing electrodes. Kubicek et al modeled the thorax
on a cylinder [11]. Bernstein later modified the equation to a truncated cone [12]. In the NICOM
an undisclosed algorithm based on age, weight and height is used for calibration.
Just like bioimpedance, it is not known precisely what the bioreactance signal truly represents.
Rather than the flow of blood, it probably reflects blood volume expansion in the aorta as the
vessel distends with the rise in blood pressure generated during systole [16]. Thus readings
may also be influenced by variations in peripheral resistance.
4.2. Continuous wave Doppler
When pressure is applied to certain solid materials, notably crystals, they produce an electric
charge. Equally, the same crystal will change shape when an electric charge is applied to it. This
is known as the piezoelectric effect. If a high frequency current (i.e. 1-10 MHz) is applied the
crystal will vibrate producing high frequency sound waves, or ultrasound. If the crystal is
place in contact with the skin the ultrasound will be propagated through the underlying tis‐
sues. When the ultrasound beam hits an interface between two tissue structures part of beam is
reflected back. If a short burst of ultrasound is used and a second crystal is used as a receiver,
then the time delays between transmission and return of this pulse can be used to create an im‐
age of the underlying tissue structure. This is the basis of ultrasound imaging.
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When a beam of continuous ultrasound encounters moving blood cells flowing In a blood
vessel the ultrasound is reflected back at a slightly altered frequency. This phenomenon is
known as the Doppler affect. The change or shift in frequency is related to the velocity of the
blood cells. The Doppler shift signal can be separated from the ultrasound signal and a profile
of the Doppler signal displayed (Figure 7). The angle (theta θ) that the ultrasound beam makes
with the direction of blood flow is also important as it affects the magnitude of the Doppler
shift frequency. If the direction of the ultrasound beam is parallel to the blood flow the Doppler
shift will be maximal, whilst a perpendicular angle of insonation produces no Doppler shift.
The angle of insonation (θ) and Doppler shift frequency are related to the cosine of theta
(cos(θ)). The velocity of the blood flow is related to the Doppler frequency by the equation
velocity =  c × fD / 2× fT cos θ,   where fD is the Doppler shift frequency, fT is the ultrasound
probe or transmitter frequency, and c is the speed of ultrasound in the tissues, 1540 m/s. The
speed of sound in air is around 340 m/s.
Figure 7. Doppler flow profiles from the oesophagus (upper - CardioQ) and the supra-sternal window (lower - US‐
COM). Velocity is shown on the y-axis (m/s) and time along x-axis. The outline of each Doppler signal is automatically
detected and drawn. The area of each envelop (stroke distance) is related to stroke volume. A series of cardiac cycles
are shown. (Upper image from Deltex Medical)
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Blood flow in  the  aorta  pulsates  rather  than being continuous,  thus  a  continuous  Dop‐
pler ultrasound signal needs to be recorded with sufficient sampling rate to show the de‐
tails  of  the  flow profile  (Figure  7).  Most  ultrasound machines  are  imaging systems and
use pulses of  ultrasound to measure distance from the probe or depth like radar or so‐
nar.  Doppler  is  different  because  it  detects  change  in  velocity  rather  than  position  and
requires a continuous ultrasound beam from a transmitting crystal and a separate receiv‐
ing crystal.  From the Doppler profile of blood flow in the aorta the peak velocity of the
blood and the duration of flow can be determined. By drawing an envelope around the
Doppler flow profile one can calculate the total  flow during systole,  which is called the
stroke (or minute) distance (Figure 7).
To convert stroke distance to a volume (i.e. stroke volume) the cross-sectional area of the blood
vessel is needed. In conventional echocardiography machines this is measured by ultrasound
imaging using the relationship CSA=  π ×d 2 / 4, where CSA = cross sectional area and d =
diameter of blood vessel.
Two Doppler cardiac output systems are currently on the market, the CardioQ (Deltex
Medical) (Figure 8) and the USCOM (USCOM Ltd.) (Figure 9). Neither measures the CSA of
the aorta directly and both estimate it but in different ways. The CardioQ uses an empirical
algorithm based on population data, where the calibration constant is based on the patient’s
age, gender, height and weight. As the CardioQ measures blood flow from descending aorta
where about 30% of the blood flow has left the aorta for the head and arms, its algorithm
corrects for this reduction in total flow. The USCOM measures blood flow across the aortic or
pulmonary valve. It uses an empirical formula to calculate valve CSA [23] which also requires
the patient’s age, gender, weight and height.
The angle of insonation with blood flow of the probe needs to be considered. When the
CardioQ is used its probe is in the oesophagus and lies parallel to the descending aorta.
The ultrasound crystals at the tip are set to 45-degrees (Figure 8). Therefore, its angle of
insonation is 45-degrees. The USCOM probe has a wide beam angle. It is directed at the
aortic or pulmonary valves and its beam axis usually lies almost parallel to the direction
of flow because of the anatomy. Thus, the angle of insonation (θ) is close to 90-degrees
and the  cosine  of  the  angle  approximates  to  1.0.  Neither  device  is  corrected  for  devia‐
tions in beam angle to blood flow.
Focusing of  the probe to obtain the optimal and maximum Doppler signal  plays an ex‐
tremely critical role in using these two Doppler devices effectively. Focusing can be per‐
formed both visually by observing the shape of  Doppler profiles  on the monitor screen
or by listening to the quality of the audible Doppler signal.  Various numbers of patient
examinations are quoted to acquire competence in the focusing technique, 12 for the Car‐
dioQ and 20  for  the  USCOM [24,25].  However,  it  takes  a  much longer  time to  become
sufficiently  familiar  with  the  different  signal  sounds  and  patterns  to  recognize  when  a
truly  reliable  signal  has  been  obtained.  Significant  experience  and  psychomotor  skill  is
needed  to  be  able  to  acquire  clinically  reliable  data,  with  the  CardioQ  being  easier  to
learn. Both companies provide training and support.
Minimally Invasive Cardiac Output Monitoring in the Year 2012
http://dx.doi.org/10.5772/54413
55
Figure 8. The CardioQ oesophageal Doppler monitor. Monitor and probe tip shown with transmitter and receiver
crystals set at a 45-degree angle. Anatomical diagram shows insertion of the probe into the oesophagus via the
mouth and insonation of the aorta which lies posterior. (Images from Deltex Medical)
Figure 9. USCOM monitor showing Doppler signal data on its screen. The flow profiles are automatically outlined to
measure stroke volumes. Below numerical readings are displayed. Lower right is a trend plot of saved cardiac output
readings. The hand held USCOM probe is shown in front of the monitor. Ultrasound gel is applied to the probe to
improve its acoustic contact.
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In addition to measuring stroke volume and cardiac output, both Doppler devices provide in‐
ternal software to (a) calculate other haemodynamic parameters, (b) display data trends and (c)
store data for future reference. One particularly useful parameter measured by these Doppler
systems is the flow time corrected (FTc), an index of preload or ventricular filling. It measures
the duration of systole corrected for heart rate. More advanced models are sold that calculate
inotropy and oxygen delivery from the blood pressure and oxygen saturation readings.
4.3. Pulse contour analysis
The arterial pulse contour method in essence is very simple. An arterial catheter is inserted into
a peripheral artery, usually the radial or femoral. The catheter is connected to a pressure trans‐
ducer which is zeroed and checked for under or over damping. The analog arterial pressure sig‐
nal is fed into a device that calculates cardiac output from the trace. However, there are at least
ten different algorithms that can be used to derive cardiac output from arterial pressure. The
theoretical basis to these different algorithms is extremely complicated and involves different
mathematical models that describe the circulation and adjust for changes in its impedance and
compliance of the peripheral circulation. A brief outline of how these algorithms is given.
a. The simplest model that describes the circulation is the pressure = flow x resistance
relationship. The area under the arterial pressure curve is directly proportional to cardiac
output providing peripheral resistance remains constant. Unfortunately, peripheral
resistance does not remain constant. It is constantly changing under the influence of the
sympathetic nervous system which helps to maintain blood pressure and the circulation
as body position changes or the person exercises.
b. Changes in peripheral resistance are reflected in diastolic pressure, so the simplest
adjustment to the model is the use of pulse pressure (i.e. systolic-diastolic) rather than the
arterial pressure to calculate cardiac output. This method is used in several pulse contour
systems.
c. The dynamics of the circulation is not as simple as pressure = flow x resistance. The
circulation is a pulsitile system and when the heart pumps the arterial system has to
expand to accommodate the additional blood. Windkessel compared the arterial system
to a capacitor and proposed a two element model of the circulation with both resistive
and capacitive components.
d. The two element model still did not describe the circulation in its entirety. Wesseling et
al added a third inductive element to compensate for time lags as blood flowed through
the arterial system [19]. Their three-element model was called “Model Flow” and was first
used in the Finapres, a finger blood pressure cuff technology.
e. Although, blood flow in the ascending aorta occurs during systole, as the blood travels
more distally a significant proportion of blood flow also occurs in diastole and this
component forms part of the peripheral arterial pressure wave. Thus, algorithms that
measure cardiac output from a peripheral site such as the radial artery also should
compensate for the diastolic component. One method is to identify the dichotic notch in
the pulse wave and thus differentiate between the systolic and diastolic components.
Minimally Invasive Cardiac Output Monitoring in the Year 2012
http://dx.doi.org/10.5772/54413
57
f. Finally, just as arterial pressure and blood flow changes over the course of one cardiac
cycle, so does the impedance and compliance of the circulation. In most Windkessel based
models the impedance and compliance remains static. The Liljestrand-Zander model
compensates for this non-linearity. Sun in his thesis on cardiac output estimation using
arterial blood pressure waveforms found the Liljestrand-Zander algorithm to be the most
robust one he tested [26].
The main pulse contour systems currently available use several of these models. The FloTrac-
Vigileo (Edwards Lifesciences) uses an empirical model based of pulse pressure and vascular
tone. The PiCCO (Pulsion) uses a Windkessel model measuring area under the pressure curve.
The LiDCO uses a similar approach but calculates the power, or root mean square (RMS),
under the pressure curve. The PRAM-MostCare (Vytech) calculates the pulsitile area under
both the systolic and diastolic curves [26,27].
Pulse contour systems need to be calibrated. The early models used a reading from a second
cardiac output measurement system, such as thermodilution. However, this proved incon‐
venient and not conducive to clinical sales. Thus, later models were designed that self
calibrated using patient demographic data. The PiCCO uses transpulmonary thermodilution
and the LiDCO-plus lithium dilution. Self calibration is performed by the FloTrac, LiDCO-
rapid and PRAM-MostCare methods (Figure 10). Normograms have been developed based
on population data and require input of the patient’s age, gender, weight and height.
Figure 10. Four main pulse contour monitors being used. FloTrac-Vigileo (top left), PiCCO with femoral artery catheter that
provides transpulmonary thermodlitation (top right), LiDCO with user card (bottom left) and PRAM-MostCare (bottom
right). LiDCO system also provides lithim dilution cardiac output. (Images downloaded from manufacturers websites)
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4.4. Nonivasive pulse contour
Very few pulse contour systems are available that measure arterial blood pressure using a
finger cuff. The most well known system is the Nexfin (BMEYE) (Figure 11). It is able to track
blood pressure from the digital artery in real time. Cardiac output is calculated from a three
element Windkessel model [19].
Figure 11. Finger cuff system used by the Nexfin. (Image from BMEYE)
4.5. Partial carbon dioxide rebreathing
In patients connected to a ventilator and breathing circuit it is possible to measure cardiac
output using a modified Fick method based on carbon dioxide. A loop of dead-space tubing
is intermittently added to the patient circuit which facilities the rebreathing of carbon dioxide
(Figure 2). Based on certain assumptions and measuring carbon dioxide levels in the circuit
cardiac output is derived. The NICO (Respironics) was the only system to be produced. The
system was not very successful because it too sensitive to interruption of the regular breathing
patterns.
5. Clinical areas & indications
5.1. Overview
MICOM has a number of desirable features: (i) It can provide continuous patient monitoring,
(ii) it is relatively safe to use clinically, and (iii) it can be simple to use. The main modalities
currently being used clinically are Doppler, pulse contour and bioreactance. These modalities
have different attributes and thus each modality works better in different clinical areas.
Bioimpedance devices are no longer in regular clinical use.
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5.2. Anaesthesia
In the operating room setting a skilled operator who can interpret haemodynamic data is nearly
always in attendance. Therefore, safety and reliability rather than ease of use are the main
issues when selecting a MICOM for anaesthesia.
Until recently cardiac output monitoring was seldom used in anaesthesia unless the patient
was having ultra-major surgery or had a significant circulatory problem. In the past a pulmo‐
nary artery catheter would have been used to monitor heart function. In more recent times the
vogue has been to use transoesophageal echocardiography (TOE), though TOE does not
measure cardiac output continuously. Thus, MICOM had not until very recently been widely
implemented in anaesthesia.
However, anaesthetic interest in MICOM has grown in recent years and this interest has been
largely driven by changes in our understanding of intra-operative fluid management [28]. Goal
directed therapies have become popular with new MICOM systems being developed to drive
protocols. The most successful of these protocols has been goal directed fluid therapy guided
by oesophageal Doppler in high risk surgical patients. A number of low powered clinical trials
attest to improved patient outcomes with its use have been published [29]. It is now being
recommended in Britain and Europe as part of enhanced surgical recovery programs [30,31].
MICOM can be used to monitor haemodynamics during major high risk surgery. It has become
popular in specialized areas of anaesthesia such as managing the circulation and intravenous
fluids of patients undergoing oesophageal surgery and there are other examples.
I will now describe the pros and cons of the main MICOM modalities with reference to
anaesthesia and operating room use.
Successful use of Doppler is very operator dependant as the probe has to be refocused regularly
to assure reliability and this can prove very time consuming and distracting for the solo
anaesthetist.
Oesophageal Doppler (CardioQ) provides continuous monitoring, but its placement in the
oesophageal limits its use to unconscious (anaesthetized) and sedated patients. Furthermore,
operations involving the head and neck or upper gastrointestinal trace may prohibit its use
because of interference with the surgical field.
External precordial Doppler (USCOM) requires use of a hand held probe that is focused via
the thoracic inlet and sternal notch on the aortic valve. The flow signal from the pulmonary
artery via the left 3rd to 5th intercostals space can also be use but is less popular in anaesthesia
because access to the anterior wall is often restricted, lung ventilation may obscure the probe
beam and repositioning of the patient to improve the signal is prohibited. During anaesthesia
the probe can be used more effectively to locate the Doppler signal from the aortic valve
because discomfort from pressure applied to the thoracic inlet is no longer felt. Readouts are
in real-time and the monitor benefits from data trending. Serial changes from up to four flow
parameters can be displayed. The type of surgery may restrict use of the probe, such as head
and neck operations and the prone position. The quality of the external Doppler signal and
thus its reliability are very patient dependant. Age appears to have major effect with reliability
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declining over the age of 50-years. A 12-point scoring system that determines the quality of
the Doppler flow profile has been described by Cattermole and this score helps to determine
whether readings are reliable [32].
Use of pulse contour cardiac output necessitates the placement of an arterial line which limits
use to more major hospital centres and high risk surgical cases. It provides continuous
monitoring and thus during anaesthesia it can be used to monitor haemodynamics and drive
goal directed protocols. Also, once set up it requires very little adjustment unlike Doppler
systems. There are least four pulse contour systems on the market. However, the reliability of
these systems in anaesthesia and intensive care has been questioned because current algo‐
rithms do not compensate for changes in peripheral resistance, particularly when vasopressor
drugs are used [33].
We do not know much about the clinical performance of bioreactance devices (NICOM,
Cheetah Medical) and whether they are more reliably when compared to bioimpedance.
However, bioreactance does have several features that make it theoretically the perfect
monitor. It is noninvasive and safe, it provides continuous cardiac output monitoring, it does
not require a great deal of skill to set up and it is inexpensive to run. It is being promoted in
the anaesthesia field as a cardiac output monitor and to drive goal directed protocols.
5.3. Intensive care
MICOM is used in intensive care to manage critically ill patients with circulatory shock and
to optimize ventilator settings such as when positive end expiratory pressure (PEEP) and lung
recruitment strategies are used. Monitoring systems that measure cardiac output accurately
are needed for bedside diagnosis, whilst reliable trending ability is needed to guide fluid and
cardiovascular drug therapies. In addition to cardiac output, oxygen delivery (DO2) and
indices of contractility are also monitored. In more stable patients such as head injuries
MICOM can be used for continuous surveillance to pick up sudden alterations in the patient’s
condition.
The use of Doppler systems is limited because the patient has to be sedated to tolerate an oeso‐
phageal probe and external Doppler does not provide continuous patient monitoring. Oeso‐
phageal Doppler was originally developed for the intensive care setting [18] and still has a role
in haemodynamic optimization, lung ventilation and driving goal directed therapies. Signal
quality can be an issue when using external Doppler (USCOM), particularly in elderly patients
with low cardiac outputs. As Doppler MICOM requires time and skill to operate and obtain re‐
liable signals, and an intensive care doctor trained in its use may not always be available, some
intensive care units have move towards training nursing staff in its use.
The use of pulse contour methods in intensive care is attractive as most critically ill patients
have an arterial line in-situ and continuous monitoring of their haemodynamic status is
required. Furthermore, once it is set up pulse contour methods require very little adjustment.
The main issue has been the reliability of current systems. It is a worrying fact that in response
to a potent vasoconstrictor such as phenylephedrine pulse contour cardiac output increases,
whereas other cardiac output modalities like thermodilution and Doppler decrease [33]. The
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algorithms currently being used to convert pressure to blood flow are still in need of improve‐
ment. The most successful pulse contour system in use in the intensive care setting is the PiCCO
plus (Pulsion) that integrates transpulmonary thermodilution readings with femoral artery
pulse contour readings. The PiCCO system can be upgraded to measure blood volume, liver
blood flow and mixed venous saturation. The FloTrac-Vigileo system (Edwards Lifesciences)
also been upgraded from just monitoring cardiac output to a more global approach in their
new EV1000 clinical platform monitor.
Functional haemodynamic monitoring has also become popular using arterial trace based
parameters  such  as  stroke  volume  (SVV)  and  pulse  pressure  (PPV)  variation  to  guide
therapy [34].
5.4. High dependency units
When MICOM is used in high dependency areas for patient monitoring continuous noninva‐
sive systems are required. Pulse contour systems can be used providing the patient has an
arterial line. The noninvasive nature of bioreactance (NICOM) makes it a potentially useful
monitor in this setting.
5.5. Accident and emergency
MICOM has two potential roles in accident and emergency (i) to facilitate resuscitate and (ii)
rapid bedside haemodynamic assessment of patients. Thus, systems that can be rapidly set up
and used at the bedside are ideal.
For resuscitation both Doppler and pulse contour methods can be used, though for pulse
contour monitoring an arterial line would need to be set up. Furthermore, a self calibrating
system would be necessary. The development of noninvasive external, supra-sternal and
precordial, Doppler (USCOM) has resulted in some novel application in the emergency
medicine setting. Assessment of cardiac output in elderly patients admitted with general
malaise can help identify early septic shock and may potentially reduce the number that need
intensive care admission. Bedside cardiac output measurement in patients with hypertension
helps one to differentiate between high peripheral resistance and high cardiac output as a cause
and helps in determining the most appropriate drug therapy.
5.6. Medicine and cardiology
NICOM in medicine contribute to the haemodynamic assessment of patients by providing
cardiac output and related measurements. They form part of multiple modality haemody‐
namic investigation systems, such as the Task Force Monitor (CNSystems), where they are
used to assess autonomic dysfunction in diabetes and postural reflexes in patients with
syncopy by head up tilting and similar tests. In cardiology they have been used to optimize
pacemaker settings. MICOM devices that are noninvasive such as bioimpedance and finger
plethysmography tend to be used.
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5.7. Paediatrics
Most MICOM modalities have been adapted for use children. Noninvasive modalities like
external Doppler (USCOM) has become increasingly popular in children because there is no
need to insert lines. It works extremely well in small children and neonates as signal acquisition
is good [35]. There is a growing interest in developing its use in paediatric intensive care for
clinical situations such as rapid identification and treatment of shock [36].
5.8. Cost and availability
When using MICOM running costs need consideration. In addition to the monitor most
systems require disposable items to operate. Oesophageal Doppler requires disposable
oesophageal probes which are made for single use (Figure 8). The FloTrac-Vigileo uses a
disposable pressure transducer (Figure 10). The PiCCO uses a femoral artery catheter that also
acts as a thermodilution catheter. The LiDCO and PRAM systems work on a credit card system
to buy user time (Figure 10). The NICOM uses purpose made skin electrodes (Figure 4). The
NICO had a disposable breathing attachment to facilitate carbon dioxide rebreathing (Figure
2). Most of these disposables are priced around the same cost as thermodilution catheter. The
only system that does not to require disposable items other than ultrasound gel is the USCOM.
The ultrasound probe is cleaned between patient uses. Financing ones supply of these
disposable items can be a problem when first introducing what is a relatively new and
unproven technology into ones clinical practice and may limit use. Manufacturers will calm
that it is a necessary evil to sustain the company financially and replay their investment in
research and development.
6. Overview of clinical validation
6.1. Main objectives
The aim of clinical validation is to determine whether a new monitor measures cardiac output
reliably, which is done by comparing its performance with that of an accepted clinical standard
such as single bolus thermodilution cardiac output. If the new monitor performs as well or
better than the reference method, it can be accepted into clinical practice.
However, there are two important aspects to reliable cardiac output measurement:
i. The accuracy of individual readings, and
ii. The ability to detect changes, or trends, between readings.
The type of clinical data and statistic analysis needed to evaluate these two aspects are different.
If ones objective is to diagnose a low or high cardiac output, then the accuracy of individual
readings in relation to the true value is of greatest importance. However, if ones objective is
to follow the change in haemodynamic response to a therapeutic intervention, then serial
cardiac output readings are needed and their absolute accuracy becomes less important,
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providing the readings reliably show the changes. This division into two roles may at first
seem a little pedantic, but a monitor that does not measure cardiac output accurately may still
be useful clinically if it detects trends reliably. As most bedside cardiac output monitors used
today are now able to measure cardiac output continuously, although many are not particu‐
larly accurate, the issue of being a reliable trend monitor becomes very relevant. Unfortunately,
the majority of published validation studies have only addressed accuracy [37].
6.2. Understanding errors
The error that arises when measuring cardiac output has two basic components:
i. Random error that arises from act of measuring and
ii. Systematic error that arises from the measurement system.
If I use a measuring tape to measure the heights of patients attending a clinic, my readings
may vary by few millimeters from the true height of each patient. This is random error. But if
the measuring tape is stretched by 2 to 3 centimeters, then every reading I take will consistently
under read the height of each patient by a few centimeters. This is a systematic error. The
division of measurement error into random and systematic components plays an important
role in the choice of statistical techniques used for validation.
One of main sources of systematic error is imprecise calibration. Calibration is performed by
(a) measuring cardiac output using a second method such as thermodilution, or (b) using
population data to derive cardiac output from the patient’s demographics, (i.e. age, height and
weight)). Unfortunately, cardiac output, and related parameters vary between individuals. In
the Nidorf normogram used to predict aortic valve size when using suprasternal Doppler
cardiac output the range of possible values about the mean for valve size at each height is ±16%
[23]. This gives rise to a significant systematic error between patients and this error impacts
upon accuracy when Bland-Altman comparisons are made against a reference method [38].
However, reliability during trending may still be preserved because trending involves a series
of readings from one single patient. Providing the systematic error remains constant, and the
random measurement errors between the series of readings are acceptably low, the monitor
can still detect changes in cardiac output reliably.
The accepted method of presenting errors in validation statistics is to use (a) percentages of
mean cardiac output and (b) 95% confidence intervals, which approximates to two standard
deviations. The term precision error is used, and should not be confused with the percentage
error which is one of the outcomes of Bland-Altman analysis.
7. Addressing statistical issues
7.1. Simple comparisons against a reference method
Validation in the clinical setting is usually performed by comparing readings from the method
being tested against a reference method. Traditionally single bolus thermodilution cardiac
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output performed using a PAC has been used. The average of three thermodilution readings
is used, and aberrant readings that differ by more than 10% are rejected, in order to improve
the precision. However, thermodilution is not a gold standard method and significant
measurement errors, both random and systematic, arise when it is used. It is generally accepted
that thermodilution has a precision error of ±20%. True gold standard methods such as aortic
flow probes have precisions errors of less than ±5%. Thus, thermodilution is an imprecise
reference method and its use greatly influences the statistical analysis. Most of the benchmarks
against which the outcomes of validation studies are judged are based on this precision of
±20%.
Other more precise and gold standard reference methods could be used, such as the Fick
method or a flow probe surgically placed on the aorta. However, in the clinical setting their
use is inappropriate and thus the current clinical standard for cardiac output measurement
thermodilution via a PAC is used. The current decline in the clinical use of PACs has left a
void. Thus, some recently published validation studies have used transpulmonary thermodi‐
lution using the PiCCO system or oesophageal Doppler monitoring using the CardioQ as
alternative reference methods.
7.2. The precision error of thermodilution
Recently, the precision of ±20% for thermodilution has come under scrutiny. The reason that
thermodilution is said to have a precision error of ±20% can be attributed to our 1999 publi‐
cation on bias and precision statistics which first proposed percentage error [39]. In the 1990’s
consensus of opinion was that for a monitor to be accepted into clinical use it should be able
to detect at least a change in cardiac output of 1 L/min when the mean cardiac output was 5
L/min, which was a 20% change [40,41]. Furthermore, Stetz and colleagues meta-analysis of
studies from the 1970’s validating the thermodilution method suggested that it had a precision
of 13-22% [42]. The 30% benchmark percentage error that everyone today quotes was based
on a precision error of ±20% for thermodilution. However, it is now seems that the precision
of thermodilution can be very variable and depends on type of patient and measurement
system used [43]. Recently Peyton and Chong have suggested that the precision of thermodi‐
lution may be as large as ±30% [44].
7.3. Study design
Study design becomes significant when ability to detection trends, in addition to accuracy, is
investigated. To determine accuracy one needs only a single pair of cardiac output readings,
test and reference, from each patient. Test refers to the new method being validated and
reference to the clinical standard thermodilution, though ideally a gold standard method
should be used. Readings, test and reference, should ideally be performed simultaneously,
because cardiac output is not a static parameter and fluctuates between cardiac cycles. The size
of the study usually includes twenty or more pairs of readings.
Study design becomes more complicated if the ability to detect trends is being investigated. A
series of paired readings from the same patient are now needed that show changes in cardiac
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output. A wide range of values of cardiac output readings is also needed. A new parameter
called delta cardiac output (∆CO) is calculated for both test and reference data which uses the
difference between consecutive readings. Trend analysis is performed on the ∆COs. The data
can be collected (a) at random or (b) at predetermined time points. Readings collected at
random can lead to uneven data distribution. Thus, a more rigid protocol with data being
collected at predetermined time points tends to be used. Commonly 6 to 10 time points are
used. A typical protocol for a patient having cardiac surgery might be: (T1) - before anaesthesia,
(T2) – after induction, (T3) - after sternotomy, (T4) – after by-pass, (T5) – after closure of the
chest and (T6-8) - at set times on the intensive care.
8. Graphical presentation and analysis
8.1. Scatter plots
Validation data first should be plotted on a graph that shows the relationship between the test
and reference cardiac output readings. The simplest approach is to plot the data on a scatter
plot where the x-axis represents the reference readings and the y-axis represents the test
readings (Figure 12). The data points should lie within close proximity to the line of identity
x=y for there to be good agreement. A regression line can be added. However, correlation is
not performed if the aim of the analysis is to assess the agreement between two methods rather
than assessing trending ability. This point was highlighted by Bland and Altman when they
published their well known method of showing agreement [45].
Figure 12. Scatter plot showing test and reference cardiac output (CO) data points. The regression line (solid) crosses
y-axis at 1.45 L/min, indicating an offset in calibration between the two methods. A line of identity (dashed) y=x is
added. There is good agreement between the test and reference methods because data points lie close to the regres‐
sion line. The correlation coefficient (r) is not provided.
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8.2. The Bland-Altman plot
The agreement between two measurement techniques, test and reference, is evaluated by cal‐
culating the bias, which is the difference between the each pair of readings, test minus refer‐
ence. In the Bland-Altman plot the bias of each pair of readings (y-axis) is plotted against the
average of the two readings (x-axis) (Figure 13). Then, three horizontal lines are added to the
plot: (a) The mean bias for all the data points and (b) The two 95% confidence interval lines for
the bias (1.96 x standard deviation of the bias) known as the “Limits of Agreement”. Sufficient
data should also be provided to allow the calculation of percentage error.
Figure 13. Bland and Altman plot showing test and reference cardiac output (CO) data points. The mean bias and
limits of agreement lines (dashed) have been added to plot. 95% of the data points falls between these limits. The
percentage error has been calculated from the mean CO and limits of agreement. Note the slightly skewed distribu‐
tion of the data shown by the sloping regression line (dotted).
8.3. Modifications to the B-A plot
i. Some investigators argue that the best estimate of cardiac output (x-axis), or the
reference value, should be used instead of the average.
ii. When the study protocol collects more than one set of data from each patient the
limits of agreement should be adjusted for repeated measures. The effect of having
multiple readings from the same subject is to reduce the influence of systematic errors,
thus decreasing the standard deviation of the bias and narrowing the limits of
agreement. As a consequence the limits become falsely small. Two recent articles
describe how to perform a correction for repeated measures [46,47]. The models used
in the two corrective methods are slightly different.
iii. The Bland-Altman plot assumes that both the test and reference methods have the
same calibrated scales for measuring cardiac output. Otherwise, the distribution of
data will be sloping and the limits of agreement falsely wide. Bland and Altman
described a logarithmic transformation to deal with this scenario [45].
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8.4. Which parameters should be present?
In the past many authors have not known how to present their cardiac output data from
validations studies in a meaningful and useful manner. When presenting data on a scatter plot
one should include the number of data points in the plot. Attention also needs to be given the
scale used on the axes so that false impressions of the spread of the data are avoided. Ideally
the axes should be of equal scale and range from zero to the maximum value of cardiac output.
If a regression line is added, the equation of line should be shown. Correlation analysis is not
required unless serial data that shows trending is being used.
Similar issues apply to the Bland-Altman plot. In particular, the range of cardiac output on the
x-axis and the range of values for bias need to be appropriate. If several plots comparing data
from several devices or patient groups are shown the scales on each plot should be equivalent.
The important data measured using the Bland-Altman analysis are:
i. The mean bias,
ii. The standard deviation of the bias which is presented as the 95% confidence intervals
or Limits of Agreement,
iii. The mean cardiac output and
iv. A calculated parameter called the percentage error.
The study size and percentage error at least should be presented with the Bland-Altman plot.
8.5. Percentage error and the 30%
The percentage error is calculated using the formula “1.96 x standard deviation of the bias /
mean cardiac output” and is expressed as a percentage. It represents a normalized version of
the limits of agreement. The percentage error enables one to compare data from different
studies when the ranges of cardiac outputs are different. Even today many authors still fail to
present percentage error.
Following a meta-analysis of data from cardiac output studies published pre-1997 that used
Bland-Altman analysis we proposed that when the percentage error was less than 28.4%, it
was reasonable to accept the new test method. However, the reference method had to be
thermodilution with an estimated precision was ±20% [39]. Our work lead to the 30% bench‐
mark for percentage error quoted in many publications over the last a decade. An error-gram
was published in our 1999 paper to allow for adjustment to this threshold when reference
methods of different precision errors were used.
8.6. Showing reliable trending ability
To assess the trending ability of a new monitor against a reference method one uses seri‐
al cardiac output readings. The simplest way to show trending is to plotting the test and
reference methods together against time (Figure 14). However, time plots only show data
from a single subject, but to confirm reliable trending data from several subjects needs to
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be shown. Also, time plots provide only graphical evidence and an objective measure of
trending is also needed.
Figure 14. Time plot showing the relationship between test and reference cardiac output readings over time. Data
pairs come from a single patient collected at intervals during surgery. The test method follows changes in reference
cardiac output despite the test method under-reading by approximately 0.75 L/min. Thus, reliable trending ability is
demonstrated in the patient.
8.7. The four-quadrant plot
The variable commonly used to assess trending in statistical analysis is delta cardiac out‐
put  (∆CO),  the  difference  between successive  readings,  or  the  change in  cardiac  output
(COb-COa).
Bland-Altman analysis does not show trending, so other analytical methods are used. There
is limited consensus on which analytical method should be used [37]. In clinical trials con‐
cordance using a four-quadrant plot has become the standard method.
The four quadrant plot is simply a scatter plot showing delta cardiac output (∆CO) for the test
method against the reference method. Because the changes in cardiac output are used, the x
and y axes pass through zero (0,0) at the centre of the plot. The delta data points should lie
along the line of identity (y=x) if good trending is present (Figure 15). The earliest reference to
this method appeared in the mid 1990’s [48,49].
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Figure 15. Four quadrant scatter plot comparing changes in test and reference cardiac output (∆CO) readings. The
plot is divided into four quadrants about the x and y axis that cross at the centre (0,0). Data points lie along the line
(dashed) of identity y = x. A square exclusion zone is drawn at the centre to remove statistical noise. Concordance
analysis is performed by counting the number of data points remaining after central zone exclusion that lie within the
two quadrants of agreement (upper right and lower left). In the plot 98% of the data concords, thus trending ability is
very good. Supra-sternal and oesophageal Doppler were being compared.
The concordance is measured as the proportion of data points in which either both methods
change in a positive direction (i.e. increase and lie within the right upper quadrant) or change
in a negative direction (i.e. decrease and lie within the left lower quadrant). Data points that
do not concord (i.e. change in different direction) lie within the upper left or lower right
quadrants. The concordance rate is the percentage of data points that are in concordance or
agree regarding the direction of change of cardiac output.
8.8. The central exclusion zone
One of the main problems encountered when using the four quadrant plot is that data points
close to its centre, which represent relatively small cardiac output changes, often do not concord
because random error effects are of similar magnitude to the cardiac output changes. This phe‐
nomenon results in statistical noise that adversely affects the concordance rate. Perrino and col‐
leagues introduced a central exclusion zone to reduce the level of these random error effects
[49].
Receiver operator characteristic (ROC) curve analysis of Perrino and colleagues data was
performed to predict the most desirable exclusion zone [48]. For a mean cardiac output of 5.0
L/min these author recommended an exclusion zone of 0.75 L/min or 15%. In the above
example it can seen that after central zone exclusion of data, most of the remaining data lie
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with the upper right (i.e. positive changes) and lower left (i.e. negative changes) quadrants of
concordance. The concordance rate is 98% as one data point lie outside these quadrants.
When performing concordance analysis one needs to know what is an acceptable rate? In a re‐
cent publication on trend analysis, we analyzed data from nine studies that used concordance
analysis. From this data we concluded that for good trending ability to be shown against ther‐
modilution as a reference method the concordance rate should be 92% or above [37].
8.9. Polar plots
Concordance analysis and the four quadrant plot have limitations. The changes in cardiac
output between the test and reference methods can be very different yet concord if both have
the same direction of change and the magnitude of the change in cardiac output plays no part
in the analysis other than determining what data is excluded. To address these issues we
developed a method of concordance analysis based on converting the data to polar coordinates.
The polar angle represented agreement whilst the radius represented the magnitude of change
in cardiac output [50]. The polar data is generated from the ∆CO(test) and ∆CO(reference).
Descriptions on how to draw polar plots are found in our paper.
Figure 16. The polar plot displays ∆CO data. The axis of the plot lies at 0-degree (and 180-degrees). It is equivalent to the
line of identity y=x on the scatter plot (figure 12), except that the plot has been rotated clockwise by 45-degrees. Concord‐
ance limits are draw at ±30-degrees. A circular exclusion zone of 0.5 L/min is draw at the centre. Data points that lies within
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these limits concord. Positive changes in cardiac output (∆CO) (right half) and negative ∆CO (left half) are presented on op‐
posite halves of the plot. The mean polar angle and radial limits of agreement for data have been omitted.
Our earliest description of polar plots used a full 360-degree circle to show both positive and
negative directional changes (Figure 16). The data points are seen to lie within narrow ±30-
degree sectors about the polar axes signifying good trending ability. When 30-degree limits
are used the allowable differences in size of ∆CO are limited to a ratio of 1 to 2, rather than just
direction of change.
The half moon plot was later developed to show positive and negative ∆CO changes together
(Figure 17).
The plot provides several parameters that describe trending:
i. The mean polar  angle  which shows the deviation in agreement  from the polar
axis  zero-degrees.  It  is  a  measure  of  difference  in  scale  between  the  test  and
reference methods.
ii. The radial limits of agreement which are 95% confidence intervals of the polar angles.
If the angles lie within the 30-degree boundaries the original x-y ΔCO values will
differ by less that 1 to 2 (i.e. half to double) in 95% of paired readings.
iii. The polar concordance rate which for comparisons against thermodilution are set at
30-degrees, but there is currently limited data to support these limits.
Artery Bypass72
Figure 17. Half-moon polar plot showing the same data as the full-circle plot, but all within the same semi-circle. The
mean polar angle and radial limits of agreement are now shown. A central exclusion zone circle removes data points
where the changes in cardiac output are small. Trending of cardiac output is good because most of the data points lie
within the 30-degrees of the polar axis (0-degrees). Concordance is performed by counting the percentage of data
points that lie within this zone. Outcomes of the polar analysis are provided with the plots. (Graphs drawn using Sig‐
ma Plot version 7.0).
The exclusion zone is used for similar reasons as in the four quadrant plot. However, as the
radial distance is mean cardiac output rather that the hypotenuse of a triangle bounded by two
cardiac output readings reference and test, its ‘size needs to be smaller by a ratio of 1 to 1.4.
Thus, rather than using 0.75 L/min or 15% as in the four quadrant plot, we used 0.5 L/min.
8.10. Making sense of the outcomes
If evidence based approaches are to be adopted when using MICOM devices in ones clinical
practice then data from clinical validation studies will need to be critically reviewed. Market‐
ing information from most manufactures of MICOM devices provide lists of publications that
they claim support their product. In reviewing such data one needs to ask the following ques‐
tions:
i. Is the study design and data appropriate?
ii. Have the correct statistics been used?
iii. Have the correct criteria been applied to results?
iv. And are the conclusions correct?
Study design is critical. (a) A sufficient number of patients should have been studied, though
calculating the power of validation studies is not easy. Comparison of study size with other
similar validation studies may help. (b) Type of patients and clinical setting effects results.
Situations where a wide range of cardiac outputs and conditions (i.e. peripheral resistance) are
encountered provide a rigorous test of performance. (c) Some of the early and more favourable
validation studies using pulse contour devices were performed in cardiac surgery patients in
whom haemodynamics were kept relatively stable. It was only when the same devices were
tested in more labile liver transplant patients with cirrhosis that the problem with these devices
and peripheral resistance became apparent [51].
The different statistical methods used in validation have been systematically covered previ‐
ously. (a) If a simple test versus reference method comparison has been performed then only
Bland-Altman analysis is needed, but make sure the outcomes of the analysis are properly
presented, including the percentage error. (b) If a sophisticated study design that allows
trending to be assessed has been used, then concordance analysis using the four quadrant plot,
and possibly a polar analysis should have been used to show trending. Check that central
exclusions zones have been applied to the ∆CO data. (c) Animal studies are slightly different
because of extent and quality of data that can be collected, and it is reasonable to use regression
analysis.
When interpreting the results of Bland-Altman analysis: (a) Make sure the precision error of
the reference method is correct. Normally for thermodilution it is ±20%, but other modalities
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may have different precisions and criteria may need correcting, like the 30% for percentage
error. (b) Make sure all the outcomes of the Bland-Altman analysis have been presented. The
key to interpreting Bland-Altman is the percentage error which needs the mean cardiac output
and limits of agreement to be calculated. (c) Make sure that the limits of agreement have been
correct for repeated measures [46,47].
When interpreting the results of concordance analysis: (a) Make sure central exclusion zones
have been used. These should be shown on the four quadrant plot. (b) Make sure the exclusion
criteria used in the plot are appropriate, usually set at 15% or 0.75 L/min when mean cardiac
output is 5 L/min. (c) Make sure the precision error of the reference method is known as this
will affect the threshold criteria for good trending. (d) When thermodilution is the reference
method a concordance rate of above 90-95% signifies good trending ability of the test method.
Polar plots are relatively new to trend analysis so their usefulness and threshold criteria
for good trending still need to be set. However, they are an excellent method of showing
trend data from multiple  patients  and for  good trending data should lie  within the 30-
degree radial limits [50].
When reading authors conclusions regarding their validation study data, be skeptical about
what is written, as the statistical analyses is often incomplete and authors tend to exaggerate
their findings. In general the percentage error should be less than 30% for good agreement and
the concordance rate above 90-95% for good trending ability.
9. Laboratory data
9.1. Advantages of animal models
Testing in animal models has two big advantages:
i. More invasive and precise gold standard methods of monitoring cardiac output can be
used, such as flow probes surgically place on the ascending aorta. Thus, the limita‐
tions of comparing against thermodilution can be avoided. The original flow probes
were electromagnetic, but today ultrasonic transit time flow probes are used.
ii. The ranges of circulatory conditions and cardiac outputs that can be studied are much
greater than in humans for ethical reasons.
9.2. Showing accuracy and trending
Bland-Altman and concordance analysis can still be used to assess accuracy and trending.
However, the ability to perform multiple readings over a range of cardiac output and condi‐
tions against a gold standard method allow the test method to be fully assessed. Regression
analysis and correlation now are the appropriate methods for analyzing the data. Regression
plots from each animal experiment are used to show how the test method behaves over a range
of cardiac output. The regression line defines the relationship between test and flow probe
methods. Correlation reflects the repeatability and trending ability of the test method, rather
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than the agreement between methods. Either r or R2 are quoted. R2 is used when a relationship
exists between the two methods. The correlation coefficient (R2) ranges from 0 to 1, where a
value > 0.9 signifies good correlation. Ideally, if the test and reference (i.e. flow probe) methods
are correctly calibrated, their data should lie along the line of identity y=x and correlation can
also be performed along this line, which is known as Lin's concordance. Alternatively, the
interclass correlation coefficient (ICC) is used. These methods were used in our 2005 paper to
validate the supra-sternal Doppler method in anaesthetized dogs [52].
9.3. Current status of technology in 2012
Bioimpedance is no longer used clinically. Bioreactance (NICOM, Cheetah Medical) has only
recently been released and still needs further clinical evaluation. It is being promoted in a wide
range of clinical areas.
Pulse contour methods have not proved universally successful because of issues with the
current algorithms failing to cope with swings in peripheral resistance. The PiCCO has a role
in intensive care for continuous cardiac output monitoring in combination with transpulmo‐
nary thermodilution. The other modalities seem more useful when used to measure “func‐
tional haemodynamic variables” such as stroke volume variation in response to the straight
leg raise test and fluid challenge. They are now being promoted to drive fluid optimization
protocols.
Oesophageal Doppler (CardioQ, Deltex Medical) appears to be a useful intra-operative and in‐
tensive care monitor of haemodynamic status. It has been used successfully to drive goal di‐
rected fluid therapy protocols in high risk surgical patients. It has recently become popular in
Britain as part of enhanced surgical recovery programs. External Doppler (USCOM) is less
commonly used but appears useful in a number of clinical settings including paediatrics.
Other MICOM technology does exist but none currently have a major role to play in developing
patient monitoring.
Nomenclature
MICOM – Minimally invasive cardiac output monitoring
TOE – Transoesophageal Echocardiography
PAC – Pulmonary Artery Catheter
CSA – Cross sectional area
LVET – Left ventricular ejection time
PEP – Pre ejection period
VEPT – Volume of electrically participating tissue
ECG – Electrocardiogram
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∆CO – delta cardiac output
Author details
Lester Augustus Hall Critchley
Address all correspondence to: hcritchley@cuhk.edu.hk
Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong,
Prince of Wales Hospital, Shatin, New Territories, Hong Kong, S.A.R.
References
[1] Booth J. A short history of blood pressure measurement. Proceedings of the Royal
Society of Medicine 1977;70(11) 793-799.
[2] Stewart GN. Researches on the circulation time and on the influences which affect it:
IV. The output of the heart. Journal of Physiosiology 1897;22 159–181.
[3] Hamilton WF, Moore JW, Kinsman JM, Spurling RG. Simultaneous determination of
pulmonary and systemic circulation times in man and of a figure related to the car‐
diac output. American Journal of Physiology 1928;84 338-344.
[4] Linton R, Band D, O'Brien T, Jonas MM & Leach R. (1997) Lithium dilution cardiac
output measurement: A comparison with thermodilution. Critical Care Medicine
1997;25(11) 1796-1800.
[5] Ganz W, Donoso R, Marcus HS, Forrester JS and Swan HJ. A new technique for
measurement of cardiac output by thermodilution in man. American Journal of Car‐
diology 1971;27 392–396.
[6] Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G and Chonette D. Catheteriza‐
tion of the heart in man with use of a flow-directed balloon-tipped catheter. New
England Journal of Medicine 1970;283(9) 447–451.
[7] Robin ED. Death by pulmonary artery flow directed catheter: Time for a moratori‐
um? Chest 1987;92(4) 727–731.
[8] Connors AF, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, Desbiens
N, Goldman L, Wu AW, Califf RM, Fulkerson WJ, Vidaillet H, Broste S, Bellamy P,
Lynn J, Knaus WA. The effectiveness of right heart catheterization in the initial care
of critically ill patients. Journal of the American Medical Association 1996;276(11)
889–897.
[9] Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W,
Williams D, Young D, Rowan K. PAC-Man study collaboration. Assessment of the
Artery Bypass76
clinical effectiveness of pulmonary artery catheters in management of patients in in‐
tensive care (PAC-Man): A randomized controlled trial. Lancet 2005;366(9484) 472–
477.
[10] Koo KK, Sun JC, Zhou Q, Guyatt G, Cook DJ, Walter SD, Meade MO. Pulmonary ar‐
tery catheters: evolving rates and reasons for use. Critical Care Medicine 2011;39(7)
1613-1618.
[11] Kubicek WG, Kottke J, Ramos MU, Patterson RP, Witsoe DA, Labree JW, Remole W,
Layman TE, Schoening H, Garamela JT. The Minnesota impedance cardiograph-
theory and applications. Biomedical Engineering. 1974;9(9) 410-416.
[12] Bernstein DP. A new stroke volume equation for thoracic electrical bioimpedance:
theory and rationale. Critical Care Medicine 1986;14(10) 904-909.
[13] Clarke DE, Raffin TA. Thoracic electrical bioimpedance measurement of cardiac out‐
put: not ready for prime time. Critical Care Medicine 1993;21(8) 1111–1112.
[14] Peng ZY, Critchley LA, Fok BS. An investigation to show the effect of lung fluid on
impedance cardiac output in the anaesthetized dog. British Journal of Anaesthesia
2005;95(4) 458-464.
[15] Critchley LA, Calcroft RM, Tan PY, Kew J, Critchley JA. The effect of lung injury and
excessive lung fluid, on impedance cardiac output measurements, in the critically ill.
Intensive Care Medicine 2000;26(6) 679-685.
[16] Kubicek WG. On the source of peak first time derivative (dZ/dt) during impedance
cardiography. Annals of Biomedical Engineering 1989;17(5) 459-462.
[17] Critchley LA. Impedance cardiography: Impact of new technology. Anaesthesia
1998;53(7) 677-685.
[18] Singer M. Oesophageal Doppler. Current Opinion in Critical Care 2009;15(3) 244-248.
[19] Wesseling KH, Jansen JR, Settels JJ, Schreuder JJ. Computation of aortic flow from
pressure in humans using a nonlinear, three-element model. Journal of Applied
Physiology 1993;74(5) 2566-2573.
[20] Cecconi M, Rhodes A. Pulse pressure analysis: to make a long story short. Critical
Care 2010;14(4) 175.
[21] Ishihara H, Sugo Y, Tsutsui M, Yamada T, Sato T, Akazawa T, Sato N, Yamashita K,
Takeda J. The ability of a new continuous cardiac output monitor to measure trends
in cardiac output following implementation of a patient information calibration and
an automated exclusion algorithm. Journal of Clinical Monitoring and Computing (E
Pub Aug 2012:26(6) 465-471)
[22] Aldrete JA, Brown C, Daily J, Buerke V. Pacemaker malfunction due to microcurrent
injection from a bioimpedance noninvasive cardiac output monitor. Journal of Clini‐
cal Monitoring 1995;11(2) 131-133.
Minimally Invasive Cardiac Output Monitoring in the Year 2012
http://dx.doi.org/10.5772/54413
77
[23] Nidorf SM, Picard MH, Triulzi MO, Thomas JD, Newell J, King ME, Weyman AE.
New perspectives in the assessment of cardiac chamber dimensions during develop‐
ment and adulthood. Journal of the American College of Cardiology 1992;19(5)
983-988.
[24] Lefrant JY, Bruelle P, Aya AG, Saïssi G, Dauzat M, de La Coussaye JE, Eledjam JJ.
Training is required to improve the reliability of esophageal Doppler to measure car‐
diac output in critically ill patients. Intensive Care Medicine 1998;24(4) 347-352.
[25] Dey I, Sprivulis P. Emergency physicians can reliably assess emergency department
patient cardiac output using the USCOM continuous wave Doppler cardiac output
monitor. Emergency Medicine Australasia. 2005;17(3) 193-199.
[26] Sun JX, Reisner AT, Saeed M, Heldt T, Mark RG. The cardiac output from blood pres‐
sure algorithms trial. Critical Care Medicine 2009;37(1): 72-80.
[27] Thiele RH, Durieux ME. Arterial waveform analysis for the anesthesiologist: past,
present, and future concepts. Anesthesia and Analgesia 2011;113(4) 766-776.
[28] Chappell D, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M. A rational approach to
perioperative fluid management. Anesthesiology 2008;109(4) 723-740.
[29] Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the
use of preemptive hemodynamic intervention to improve postoperative outcomes in‐
moderate and high-risk surgical patients. Anesthesia and Analgesia 2011;112(6)
1392-1402.
[30] Kehlet H, Mythen M. Why is the surgical high-risk patient still at risk? British Journal
of Anaesthesia 2011;106(3) 289–291.
[31] Mythen MG, Swart M, Acheson N, Crawford R, Jones K, Kuper M, McGrath JS, Hor‐
gan A. Perioperative fluid management: Consensus statement from the enhanced re‐
covery partnership. Perioperative Medicine 2012;1(1) 2.
[32] Cattermole GN, Leung PYM, Tang CO, Smith BE, Graham CA, Rainer TH. A new
method to score the quality of USCOM scans (Abstract 14). Hong Kong Journal of
Emergency Medicine 2009;16(4) 288.
[33] Meng L, Tran NP, Alexander BS, Laning K, Chen G, Kain ZN, Cannesson M. The im‐
pact of phenylephrine, ephedrine, and increased preload on third-generation Vigileo-
FloTrac and esophageal Doppler cardiac output measurements. Anesthesia and
Analgesia 2011;113(4) 751-757.
[34] Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform de‐
rived variables and fluid responsiveness in mechanically ventilated patients: a sys‐
tematic review of the literature. Critical Care Medicine 2009;37(9) 2642–2647.
Artery Bypass78
[35] He SR, Zhang C, Liu YM, Sun YX, Zhuang J, Chen JM, Madigan VM, Smith BE, Sun
X. Accuracy of the ultrasonic cardiac output monitor in healthy term neonates during
postnatal circulatory adaptation. China Medical Journal 2011;124(15) 2284-2289.
[36] Brierley J, Peters MJ. Distinct hemodynamic patterns of septic shock at presentation
to pediatric intensive care. Pediatrics 2008;122(4) 752-759.
[37] Critchley LA, Lee A, Ho AM. A critical review of the ability of continuous cardiac
output monitors to measure trends in cardiac output. Anesth. Analg. 2010;111(5)
1180-1192.
[38] Chong SW, Peyton PJ. A meta-analysis of the accuracy and precision of the ultrasonic
cardiac output monitor (USCOM). Anaesthesia 2012;67(11) 1266-1271.
[39] Critchley LA, Critchley JA: A meta-analysis of studies using bias and precision statis‐
tics to compare cardiac output measurement techniques. Journal of Clinical Monitor‐
ing and Computing 1999;15(2) 85–91.
[40] LaMantia KR, O’Connor T, Barash PG: Comparing methods of measurement: An al‐
ternative approach. Anesthesiology 1990;72(5) 781–783.
[41] Wong DH, Tremper KK, Stemmer EA, O’Connor D, Wilbur S, Zaccari J, Reeves C,
Weidoff P, Trujillo RJ: Noninvasive cardiac output: Simultaneous comparison of two
different methods with thermodilution. Anesthesiology 1990; 72(5) 784 –792.
[42] Stetz CW, Miller RG, Kelly GE, Raffin TA. Reliability of the thermodilution method
in the determination of cardiac output in clinical practice. American review of respi‐
ratory disease 1982;126(6) 1001–1004.
[43] Yang XX, Critchley LA, Joynt GM. Determination of the measurement error of the
pulmonary artery thermodilution catheter using in-vitro continuous flow test rig.
Anesthesia and Analgesia 2011;112(1) 70-77.
[44] Peyton PJ, Chong SW. Minimally invasive measurement of cardiac output during
surgery and critical care: a meta-analysis of accuracy and precision. Anesthesiology
2010;113(5) 1220-1235.
[45] Bland JM, Altman DG. Statistical methods for assessing agreement between two
methods of clinical measurement. Lancet 1986;1(8476) 307-310.
[46] Bland JM, Altman DG. Agreement between methods of measurement with multiple
observations per individual. Journal of Biopharmaceutical Statistics 2007;17(4) 571–
582.
[47] Myles PS, Cui J. Using the Bland–Altman method to measure agreement with repeat‐
ed measures. British Journal of Anaesthesia 2007;99(3) 309–311.
[48] Perrino AC, O’Connor T, Luther M. Transtracheal Doppler cardiac output monitor‐
ing: comparison to thermodilution during noncardiac surgery. Anesthesia and Anal‐
gesia 1994;78(6) 1060–1066.
Minimally Invasive Cardiac Output Monitoring in the Year 2012
http://dx.doi.org/10.5772/54413
79
[49] Perrino AC, Harris SN, Luther MA. Intraoperative determination of cardiac output
using multiplane transesophageal echocardiography: a comparison to thermodilu‐
tion. Anesthesiology 1998;89(2) 350–357.
[50] Critchley LA, Yang XX, Lee A: Assessment of trending ability of cardiac output mon‐
itors by polar plot methodology. Journal of Cardiothoracic and Vascular Anesthesia
2011;25(3) 536-546.
[51] Biancofiore G, Critchley LA, Lee A, Bindi L, Bisa` M, Esposito M, Meacci L, Mozzo R,
DeSimone P, Urbani L, Filipponi F. Evaluation of an uncalibrated arterial pulse con‐
tour cardiac output monitoring system in cirrhotic patients undergoing liver surgery.
British Journal of Anaesthesia 2009;102(1) 47–54.
[52] Critchley LAH, Peng ZY, Fok BS, Flach J, Wong SC, Lee A, Phillips RA. Testing the
reliability of a new ultrasonic cardiac output monitor, the USCOM using aortic flow
probes in anaesthetized dogs. Anesthesia and Analgesia 2005;100(3) 748-753.
Artery Bypass80
